Terms: = Lung cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
390 results:
1. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway.
Ci M; Zhao G; Li C; Liu R; Hu X; Pan J; Shen Y; Zhang G; Li Y; Zhang L; Liang P; Cui H
Cell Death Dis; 2024 Mar; 15(3):179. PubMed ID: 38429268
[TBL] [Abstract] [Full Text] [Related]
2. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract] [Full Text] [Related]
3. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of LSD1 induces ferroptosis through the ATF4-xCT pathway and shows enhanced anti-tumor effects with ferroptosis inducers in NSCLC.
Du L; Yang H; Ren Y; Ding Y; Xu Y; Zi X; Liu H; He P
Cell Death Dis; 2023 Nov; 14(11):716. PubMed ID: 37923740
[TBL] [Abstract] [Full Text] [Related]
5. Genomic insights into the mechanisms of fgfr1 dependency in squamous cell lung cancer.
Mäkinen N; Meyerson M
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37909331
[TBL] [Abstract] [Full Text] [Related]
6. Discovery of 4-((3,4-dichlorophenyl)amino)-2-methylquinolin-6-ol derivatives as EGFR and HDAC dual inhibitors.
Qian Y; Zhou S; Li J; Ma M; Chen H; Cao Y; Zhang Y; Sun C; Li K; Liu Y; Dai S; Ao M; Fang M; Wu Z; Li M
Eur J Pharmacol; 2023 Dec; 960():176114. PubMed ID: 37863412
[TBL] [Abstract] [Full Text] [Related]
7. Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation.
Lu P; Leslie F; Wang H; Sodhi A; Choi CY; Pekosz A; Cui H; Jia H
J Control Release; 2023 Dec; 364():1-11. PubMed ID: 37858626
[TBL] [Abstract] [Full Text] [Related]
8. B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC.
Chen B; Zheng K; Fang S; Huang K; Chu C; Zhuang J; Lin J; Li S; Yao H; Liu A; Liu G; Lin J; Lin X
J Nanobiotechnology; 2023 Oct; 21(1):378. PubMed ID: 37848956
[TBL] [Abstract] [Full Text] [Related]
9. FGF2 drives osteosarcoma metastasis through activating fgfr1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
10. Characterization of histone chaperone MCM2 as a key regulator in arsenic-induced depletion of H3.3 at genomic loci.
Wu P; Lin SJ; Chen D; Jin C
Toxicol Appl Pharmacol; 2023 Oct; 477():116697. PubMed ID: 37734572
[TBL] [Abstract] [Full Text] [Related]
11. Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.
Pace A; Scirocchi F; Napoletano C; Zizzari IG; Po A; Megiorni F; Asquino A; Pontecorvi P; Rahimi H; Marchese C; Ferretti E; Nuti M; Rughetti A
J Transl Med; 2023 Sep; 21(1):626. PubMed ID: 37715207
[TBL] [Abstract] [Full Text] [Related]
12. The utility of H2 receptor antagonists in preventing infusion-related reactions to paclitaxel chemotherapy.
Tsang C; Robinson J; Wheatley-Price PF; Brule SY; Moore SM
Cancer; 2023 Dec; 129(23):3815-3819. PubMed ID: 37665180
[TBL] [Abstract] [Full Text] [Related]
13. Somatic rearrangements causing oncogenic ectodomain deletions of fgfr1 in squamous cell lung cancer.
Malchers F; Nogova L; van Attekum MH; Maas L; Brägelmann J; Bartenhagen C; Girard L; Bosco G; Dahmen I; Michels S; Weeden CE; Scheel AH; Meder L; Golfmann K; Schuldt P; Siemanowski J; Rehker J; Merkelbach-Bruse S; Menon R; Gautschi O; Heuckmann JM; Brambilla E; Asselin-Labat ML; Persigehl T; Minna JD; Walczak H; Ullrich RT; Fischer M; Reinhardt HC; Wolf J; Büttner R; Peifer M; George J; Thomas RK
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37606995
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.
Glaser M; Rasokat A; Prang D; Nogova L; Wömpner C; Schmitz J; Bitter E; Terjung I; Eisert A; Fischer R; John F; von Levetzow C; Michels S; Riedel R; Ruge L; Scharpenseel H; Siebolts U; Merkelbach-Bruse S; Buettner R; Brägelmann J; Wolf J; Scheffler M
Lung Cancer; 2023 Oct; 184():107344. PubMed ID: 37579577
[TBL] [Abstract] [Full Text] [Related]
15. Antibody-Drug Conjugates in lung cancer: Recent Advances and Implementing Strategies.
Passaro A; Jänne PA; Peters S
J Clin Oncol; 2023 Jul; 41(21):3747-3761. PubMed ID: 37224424
[TBL] [Abstract] [Full Text] [Related]
16. Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer.
Sandström Gerdtsson A; Knulst M; Botling J; Mezheyeuski A; Micke P; Ek S
Oncoimmunology; 2023; 12(1):2206725. PubMed ID: 37139184
[TBL] [Abstract] [Full Text] [Related]
17. B7-H3 but not PD-L1 is involved in the antitumor effects of Dihydroartemisinin in non-small cell lung cancer.
Hu BQ; Huang JF; Niu K; Zhou J; Wang NN; Liu Y; Chen LW
Eur J Pharmacol; 2023 Jul; 950():175746. PubMed ID: 37105515
[TBL] [Abstract] [Full Text] [Related]
18. Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments.
Omori S; Muramatsu K; Kawata T; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Sugino T; Takahashi T
Invest New Drugs; 2023 Apr; 41(2):356-364. PubMed ID: 37036580
[TBL] [Abstract] [Full Text] [Related]
19. Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma.
Sumimoto H; Takano A; Igarashi T; Hanaoka J; Teramoto K; Daigo Y
Sci Rep; 2023 Mar; 13(1):5087. PubMed ID: 36991099
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell lung cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
[TBL] [Abstract] [Full Text] [Related]
[Next]
